Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The History of ACE Inhibitors in Scleroderma Renal Crisis

Ruth Jessen Hickman, MD  |  Issue: February 2021  |  February 16, 2021

Diagnosing scleroderma renal crisis can sometimes be a challenge, particularly if it is the first presenting symptom of scleroderma.

Entrance of the Ace Inhibitors

When the kidney senses it isn’t getting enough blood, it secretes renin, which acts on the protein angiotensinogen to produce angiotensin I. In the 1950s, researchers discovered the enzyme that could transform angiotensin I to angiotensin II, a powerful vasoconstrictor.7 Dr. Whitman explains, “All the blood vessels in your body start constricting, and let’s say you have a finite amount of salt and water and blood circulating. Your blood vessels go into spasms, and your blood pressure shoots up.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This angiotensin-converting enzyme (ACE) eventually attracted attention as a drug target. This eventually led to the breakthrough development of the first successful oral ACE inhibitor, captopril, in the 1970s, which displayed a clear anti­hypertensive effect.7

John H. Laragh, MD, was one of the pioneers in the study of the renin-angiotensin system and hypertension. He and others were exploring the role of ACE inhibitors in the potential treatment of essential hypertension at the Hypertension-Cardiovascular Center at the New York Hospital–Cornell Medical Center.8

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers had hypothesized that elevated renin might play a pathological role in scleroderma renal crisis, based on animal studies and some earlier case reports. Dr. Steen says, “The ACE inhibitors were a brand-new class of medications. John Laragh was working on it for hypertension, and by around that time they knew that scleroderma was a renin-driven hypertension type of thing, so it was natural to try it.”

In 1977, Dr. Laragh and his colleagues published “Reversal of Vascular and Renal Crises of Scleroderma by Oral Angiotensin-Converting-Enzyme Blockade,” the first case report to describe the effects of an ACE inhibitor on scleroderma renal crisis.6 It detailed the stories of two scleroderma patients who displayed dramatic reversal of their renal crisis in response to captopril (SQ 14225), which had not yet been released publicly. The authors proposed that captopril, if used at the first sign of scleroderma renal crisis, might provide a powerful tool to protect against renin-induced vasoconstriction and so prevent life-threatening vascular damage.

Dr. Steen

Dr. Steen

Dr. Steen was pursuing a fellowship in rheumatology at the University of Pittsburgh, where she worked under the esteemed rheumatologist Gerald P. Rodnan, MD. She recalls that Dr. Rodnan was in communication with William A. D’Angelo, MD, a co-author and one of the physicians collaborating with Dr. Laragh. 

As a fellow, Dr. Steen herself treated “patient 2,” a 25-year-old student with newly diagnosed severe scleroderma. She recounts that he and his family were in Florida over the holidays. “We got a call that he was in the emergency room with a blood pressure of 220 over 120. Dr. Rodnan had just found out about this drug and its availability, and he made it all happen.” They arranged to have him flown back to New York City for treatment. She adds, “We literally saved his life with this drug.”

Other reports soon followed. In 1981, another case study out of University of California, Los Angeles, described four patients with scleroderma renal crisis successfully treated with captopril.9 Another key study came out in 1982 from Dr. Laragh’s group working in collaboration with Dr. LeRoy: Variable Response to Oral Angiotensin-Converting-Enzyme Blockade in Hypertensive Scleroderma Patients.10 

Dr. Whitman, the study’s first author, first began working with Dr. Laragh during a second-year resident elective at the Hypertension Center. Dr. Laragh asked his resident to study the response to captopril in his patients with scleroderma who had hypertension. He began treating these patients shortly before captopril’s FDA approval for essential hypertension. 

Dr. Whitman analyzed seven patients with scleroderma renal crisis as well as a group of five patients with hyper­tensive urgency. Blockade of the angiotensin system effectively controlled blood pressure in all the patients. Five out of the seven patients with scleroderma renal crisis progressed to renal failure despite this, suggesting that their renal function had already been too compromised.10 

Dr. Whitman explains, “If we didn’t get them on the captopril before their serum creatinine began to climb very rapidly, specifically a value about 2.5, they went ahead and went into renal failure. But if we gave them the medication before their serum creatinine got worse, we were able to stop them from getting malignant hypertension.”

Dr. Whitman notes that although this article received a lot of publicity, many other centers around the country were working on the topic, particularly the University of Pittsburgh. He adds, “We just happened to get more patients faster because we were working not only out of a rheumatology group of patients but also a hypertension center that was well known and run by Dr. Laragh, who was a very famous guy.”

Dr. Steen recounts that ACE inhibitors for scleroderma renal crisis moved into practice rapidly. Dr. Steen, Dr. Rodnan, Dr. D’Angelo and Dr. LeRoy planned to do a trial comparing captopril with minoxidil. She adds, “Then the drug came out, and nobody would enter anybody into the study, because people were finding out that the drug worked so miraculously that they wouldn’t even consider doing a controlled trial with another drug. You could give them this drug, and it was so dramatic—you could just see it. Particularly because, before then, almost everyone died.”

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsSystemic Sclerosis Tagged with:Lost & FoundRenal disease

Related Articles
    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    February 17, 2018

    The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….

    Can Technology Help Solve Scleroderma Renal Crisis?

    December 1, 2010

    A case study in using the Internet to facilitate rare disease research

    Case Report: A Patient Develops Scleroderma Renal Crisis

    October 18, 2019

    Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis. SRC occurs in 2–15% of patients with diffuse sclerosis and usually within the first five years from the time of diagnosis. Risk factors for SRC include, but are not limited to, early diagnosis, corticosteroid or cyclosporine use, and the presence of anti-RNA polymerase III…

    How to Manage Pain in Patients with Renal Insufficiency or End-Stage Renal Disease on Dialysis

    October 1, 2013

    Narcotic and non-narcotic pain regimens can be used

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences